With data from nine-patient study, VectivBio raises $125M ahead of lead program's big readout
VectivBio now has $125 million more to work with.
The Basel, Switzerland-based biotech reported the raise just 20 minutes after it dropped early data from a small, open-label study on its lead candidate, apraglutide, a GLP2 agonist for short bowel syndrome with intestinal failure, or SBS-IF, a rare condition in which the body can’t absorb enough nutrients because the intestines are too short.
The open-label, Phase II study in question only enrolled nine patients with SBS-IF and colon in continuity, a subgroup of patients that VectivBio CEO Luca Santarelli dubbed the “underserved majority.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
